Drugs / Pediacel®
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials · 2 met primary | ||||||
| Phase 3 | NCT01839188 | May 2013 → Mar 2014 | meningococcal infection, viral infectious disease | MCM Vaccines B.V. | Completed | Met primary |
| Phase 3 | NCT00652951 | Apr 2008 → May 2009 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00384059 | Oct 2006 → Oct 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00343421 | Jul 2006 → Jun 2008 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT00871338 Comparator | Jun 2009 → Mar 2010 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00990080 Comparator | May → Jul 2010 | — | Dalhousie University | Completed | No outcome recorded |
| Phase 4 | NCT02447718 Comparator | Nov 2015 → Mar 2018 | acute lymphoblastic leukemia | Canadian Immunization Research Network | Completed | No outcome recorded |
| Phase 4 | NCT02002156 Background | Jun 2014 → Aug 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pediacel | “Pediacel® at 2 and 4 Months of Age Followed By One Dose of Infanrix™ IPV/Hib at 6 Months of Age” NCT00990080 ↗ |
| Known as | Pediacel, Sanofi Pasteur MSD Ltd. | “Pediacel®, Sanofi Pasteur MSD Ltd.” NCT02002156 ↗ |
| Modality | Vaccine | “PEDIACEL®: DT5aP-IPV-Hib 5-component Pertussis vaccine” NCT00343421 ↗ |
| Route | Intramuscular | “0.5 mL each, IM (opposite thigh)” NCT00343421 ↗ |